Delayed Recognition of Wolfram Syndrome Frequently Misdiagnosed as Type 1 Diabetes with Early Chronic Complications

Abstract

Aims:

Improvements in diagnostic methods and greater genetic awareness have brought remarkable progress in the recognition of monogenic forms of diabetes, including Wolfram syndrome (WFS). WFS is diagnosed based on clinical criteria of coexistence of diabetes mellitus and optic atrophy, and confirmed by molecular analysis; however, the condition is still sometimes misdiagnosed. To begin to understand the reasons for misdiagnosis, we conducted a retrospective analysis of WFS patients who were originally misdiagnosed.

Materials and methods:

The medical histories of 13 pediatric patients with clinical misdiagnosis of type 1 diabetes and early chronic complications made in the years 1995–2010 and who were subsequently correctly diagnosed with WFS based on genetic testing in 2008–2011 were analyzed.

Results:

The average age of the patients at diabetes onset was 5 (4.4–6.3) years, and the mean HbA1c level at diagnosis was 9.1±2.3%. Initially, all of these patients were treated as having type 1 diabetes with progressive visual impairment despite good metabolic control (mean HbA1c 7.5±1.3%). Diagnosis of optic atrophy was made at an average age of 9 (5.9–11.5) years, which corresponds to 4 years after diabetes recognition (p=0.002). At the time of genetic analysis, the average age of the patients was 16 (12–18.7) years, which corresponds to 7 years after recognition of coexistence of diabetes mellitus and optic atrophy (p=0.007).

Conclusions:

Delays of at least 7 years occurred before recognition of WFS among a cohort of pediatric patients with diabetes. All patients with WFS were primarily misdiagnosed as having type 1 diabetes.

Key words

Wolfram syndrome - monogenic diabetes - type 1 diabetes

• References

• 1 Howson JM, Stevens H, Smyth DJ et al. Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes 2011; 60: 2635-2644
• 2 Long AE, Gillespie KM, Rokni S et al. Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes 2012; 61: 683-686
• 3 Kytö JP, Harjutsalo V, Forsblom C et al. Decline in the cumulative incidence of severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care 2011; 34: 2005-2007
• 4 Downie E, Craig ME, Hing S et al. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care 2011; 34: 2368-2373
• 5 Minton JAL, Rainbow LA, Ricketts C et al. Wolfram syndrome. Rev End & Metabol Dis 2003; 4: 53-59
• 6 Zmyslowska A, Borowiec M, Antosik K et al. Wolfram syndrome in the Polish population: novel mutations and genotype-phenotype correlation. Clin Endocrinol (Oxf) 2011; 75: 636-641
• 7 Van Den Ouweland JMW, Cryns K, Pennings RJE et al. Molecular characterization of WFS1 in patients with Wolfram syndrome. J Mol Diagn 2003; 5: 88-95
• 8 Zalloua PA, Azar ST, Delépine M et al. WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon. Hum Mol Genet 2008; 17: 4012-4021
• 9 Zubkiewicz-Kucharska A, Noczyńska A. Epidemiology of type 1 diabetes in Lower Silesia in the years 2000–2005. Pediatr Endocrinol Diabetes Metab 2010; 16: 45-49
• 10 Jarosz-Chobot P, Polanska J, Szadkowska A et al. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 2011; 54: 508-515
• 11 Rohayem J, Ehlers C, Wiedemann B et al. Wolfram Syndrome Diabetes Writing Group . Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype. Diabetes Care 2011; 34: 1503-1510
• 12 Cano A, Molines L, Valéro R et al. French Group of Wolfram Syndrome . Microvascular Diabetes Complications in Wolfram Syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness [DIDMOAD]). Diabetes Care 2007; 30: 2327-2330
• 13 Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995; 346 (8988) 1458-1463
• 14 Giuliano F, Bannwarth S, Monnot S et al. French Group of WS . Wolfram syndrome in French population: characterization of novel mutation in the WFS1 gene. Human mutation 2005; mutation in brief# 771 online
• 15 Cano A, Rouzier C, Monnot S et al. French Group of Wolfram Syndrome, Vialettes B . Identification of novel mutations in WFS1 and genotype-phenotype correlation in Wolfram syndrome. Am J Med Genet 2007; 143: 1605-1612
• 16 Medlej R, Wasson J, Baz P et al. Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab 2004; 89: 1656-1661
• 17 Baz P, Azar ST, Medlej R et al. Role of early fundoscopy for diagnosis of Wolfram syndrome in type 1 diabetic patients. Diabetes Care 1999; 22: 1376-1378
• 18 Minton JA, Hattersley AT, Owen K et al. Association studies of genetic variation in the WFS1 gene and type 2 diabetes in U.K. populations. Diabetes 2002; 51: 1287-1290
• 19 Ohata T, Koizumi A, Kayo T et al. Evidence of an increased risk of hearing loss in heterozygous carriers in a Wolfram syndrome family. Hum Genet 1998; 103: 470-474
• 20 Furlong RA, Ho LW, Rubinsztein JS et al. A rare coding variant within the wolframin gene in bipolar and unipolar affective disorder cases. Neurosci Lett 1999; 277: 123-126
• 21 Titah SM, Meunier I, Blanchet C et al. Cataract as a phenotypic marker for a mutation in WFS1, the Wolfram syndrome gene. Eur J Ophthalmol 2012; 22: 254-258